{
  "0": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "1": "Here are the NCT IDs for the completed interventional studies for gout with the main interventions pegloticase or placebo that started in May 2006 in the United States:\n\n1. [NCT03994731](https://clinicaltrials.gov/ct2/show/NCT03994731)\n2. [NCT03303989](https://clinicaltrials.gov/ct2/show/NCT03303989)\n3. [NCT00325195](https://clinicaltrials.gov/ct2/show/NCT00325195)\n4. [NCT01356498](https://clinicaltrials.gov/ct2/show/NCT01356498)\n\nYou can click on the links to view the details of each study. Let me know if you'd like more information about any of them!",
  "2": "The PMID of the article is **40483449**.",
  "3": "The PMID for the article titled “Trends in self-citation rates in high-impact neurology, neuroscience, and psychiatry journals,” authored by Rosenblatt M and published in eLife in 2025, is **40366360**.",
  "4": "For the target with Ensembl ID **ENSG00000140443** (approved symbol **IGF1R**), the following tractability information is available where the value is **True**:\n\n### Small Molecule (SM) Modality:\n- Approved Drug\n- Structure with Ligand\n- High-Quality Ligand\n- High-Quality Pocket\n- Druggable Family\n\n### Antibody (AB) Modality:\n- Approved Drug\n- UniProt loc high conf\n- GO CC high conf\n- UniProt SigP or TMHMM\n\n### Protein (PR) Modality:\n- Literature\n- UniProt Ubiquitination\n- Database Ubiquitination\n- Half-life Data\n- Small Molecule Binder\n\n### Other Clinical (OC) Modality:\n- Approved Drug\n\nThis indicates that IGF1R is highly tractable across multiple modalities, with strong evidence supporting its potential as a drug target.",
  "5": "The unique PMID of the article titled “Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis,” authored by Cao H and published in *Frontiers in Immunology* in 2025, is **39958333**.",
  "6": "The following diseases are associated with the target ERBB2 (Ensembl ID ENSG00000141736) in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Non-small cell lung carcinoma** (Score: 0.757)\n2. **Cancer** (Score: 0.732)\n3. **Breast carcinoma** (Score: 0.699)\n4. **Neoplasm** (Score: 0.675)\n5. **Gastric cancer** (Score: 0.666)\n6. **Breast adenocarcinoma** (Score: 0.636)\n7. **Breast cancer** (Score: 0.634)\n8. **Lung adenocarcinoma** (Score: 0.625)\n9. **Urinary bladder carcinoma** (Score: 0.611)\n10. **Breast neoplasm** (Score: 0.611)\n11. **Lung cancer** (Score: 0.600)\n12. **HER2 Positive Breast Carcinoma** (Score: 0.583)\n13. **Gastric adenocarcinoma** (Score: 0.565)\n14. **Glomerular filtration rate** (Score: 0.557)\n15. **Urinary bladder cancer** (Score: 0.540)\n16. **Ovarian cancer** (Score: 0.532)",
  "7": "The PMID of the article is **40311855**.",
  "8": "For the target with Ensembl ID **ENSG00000239732** (approved symbol **TLR9**), the following tractability information is available where the value is **True**:\n\n1. **Small Molecule (SM)**:\n   - Approved Drug\n   - High-Quality Ligand\n   - Druggable Family\n\n2. **Antibody (AB)**:\n   - GO CC high confidence\n   - UniProt Signal Peptide or TMHMM\n\n3. **Protein (PR)**:\n   - Database Ubiquitination\n   - Small Molecule Binder\n\n4. **Other Clinical (OC)**:\n   - Advanced Clinical\n\nThis indicates that TLR9 is tractable across multiple modalities, including small molecules, antibodies, and protein-based approaches, with some evidence supporting its clinical relevance.",
  "9": "The following diseases are associated with the target VEGFA (Ensembl ID: ENSG00000112715) with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Diabetic retinopathy** (Score: 0.693)\n2. **Age-related macular degeneration** (Score: 0.667)\n3. **Wet macular degeneration** (Score: 0.648)\n4. **Macular retinal edema** (Score: 0.610)\n5. **Non-small cell lung carcinoma** (Score: 0.609)\n6. **Breast cancer** (Score: 0.606)\n7. **Glioblastoma multiforme** (Score: 0.598)\n8. **Neoplasm** (Score: 0.586)\n9. **Ovarian cancer** (Score: 0.580)\n10. **Renal cell carcinoma** (Score: 0.569)\n11. **Macular degeneration** (Score: 0.556)\n12. **Ocular vascular disease** (Score: 0.553)\n13. **Hematocrit** (Score: 0.553)\n14. **Colorectal neoplasm** (Score: 0.548)\n15. **Hemoglobin measurement** (Score: 0.545)\n16. **Colorectal adenocarcinoma** (Score: 0.537)\n17. **Erythrocyte count** (Score: 0.535)\n18. **Cervical cancer** (Score: 0.526)\n19. **Neutrophil count** (Score: 0.517)\n20. **Platelet count** (Score: 0.516)\n21. **Leukocyte count** (Score: 0.516)\n22. **HbA1c measurement** (Score: 0.508)\n23. **Ovarian carcinoma** (Score: 0.505)\n24. **Macrovascular complications of diabetes** (Score: 0.503)\n\nThese diseases span a range of conditions, including cancers, ocular diseases, and metabolic disorders.",
  "10": "It appears there are no PubMed articles matching the exact title and author you provided for the year 2025. This could be due to the article not being indexed yet, the details being incorrect, or the article not existing in PubMed. \n\nWould you like to refine your search or check for similar articles?",
  "11": "The unique PMID for the article titled “On tending sprouts: empowering emerging immunologists in Latin America,” authored by Brunck MEG and published in *Trends in Immunology* in 2025, is **40050163**.",
  "12": "It seems that the article titled “Vogt Koyanagi Harada disease with bilateral disc edema diagnosed as Arnold Chiari malformation with papilledema: The blurred margin between ophthalmology and neurology,” authored by Agrawal A and published in the Indian Journal of Ophthalmology in 2025, does not currently have a PMID listed in PubMed. \n\nIf you have additional details or if the article is very recent, it might not yet be indexed in PubMed. You may want to check the journal's website or other academic databases for further information. Let me know if you'd like assistance with any other queries!",
  "13": "The article titled \"[Exploring screening practices for sexual disorders in breast cancer patients]\" by Jacquet C, published in *Soins; la revue de reference infirmiere* in 2025, does not appear to be indexed in PubMed based on the provided search criteria. \n\nIf you have additional details or alternative search terms, I can refine the search further. Alternatively, the article might not yet be indexed or may be available in a different database. Would you like me to try a broader search?",
  "14": "There are currently no recruiting interventional studies in ClinicalTrials.gov that started in June 2022 and are investigating Bexmarilimab in Finland. If you'd like, I can expand the search to include other countries or timeframes. Let me know!",
  "15": "The unique PMID for the article is **40122575**.",
  "16": "Here are the completed interventional studies from ClinicalTrials.gov that match your criteria:\n\n1. **NCT00355134**  \n2. **NCT00340834**  \n3. **NCT00662649**  \n4. **NCT00289978**  \n\nThese studies involve Fingolimod (1.25 mg or 0.5 mg) or Placebo, started in January 2006 or later, and were conducted in Australia. Let me know if you'd like more details about any of these studies.",
  "17": "Here is a list of completed interventional studies for metastatic breast cancer with Eribulin Mesylate as the main intervention conducted in the United States, as found on ClinicalTrials.gov:\n\n1. [NCT01269346](https://clinicaltrials.gov/ct2/show/NCT01269346)\n2. [NCT02915744](https://clinicaltrials.gov/ct2/show/NCT02915744)\n3. [NCT01492101](https://clinicaltrials.gov/ct2/show/NCT01492101)\n4. [NCT01908101](https://clinicaltrials.gov/ct2/show/NCT01908101)\n5. [NCT02120469](https://clinicaltrials.gov/ct2/show/NCT02120469)\n6. [NCT03262935](https://clinicaltrials.gov/ct2/show/NCT03262935)\n7. [NCT03901339](https://clinicaltrials.gov/ct2/show/NCT03901339)\n8. [NCT01795586](https://clinicaltrials.gov/ct2/show/NCT01795586)\n9. [NCT02513472](https://clinicaltrials.gov/ct2/show/NCT02513472)\n10. [NCT02581839](https://clinicaltrials.gov/ct2/show/NCT02581839)\n11. [NCT01268150](https://clinicaltrials.gov/ct2/show/NCT01268150)\n12. [NCT01837095](https://clinicaltrials.gov/ct2/show/NCT01837095)\n13. [NCT02574455](https://clinicaltrials.gov/ct2/show/NCT02574455)\n14. [NCT03430518](https://clinicaltrials.gov/ct2/show/NCT03430518)\n15. [NCT02481050](https://clinicaltrials.gov/ct2/show/NCT02481050)\n16. [NCT01945775](https://clinicaltrials.gov/ct2/show/NCT01945775)\n17. [NCT01827787](https://clinicaltrials.gov/ct2/show/NCT01827787)\n18. [NCT01802970](https://clinicaltrials.gov/ct2/show/NCT01802970)\n19. [NCT01401959](https://clinicaltrials.gov/ct2/show/NCT01401959)\n20. [NCT03051659](https://clinicaltrials.gov/ct2/show/NCT03051659)\n21. [NCT00337103](https://clinicaltrials.gov/ct2/show/NCT00337103)\n22. [NCT02014337](https://clinicaltrials.gov/ct2/show/NCT02014337)\n23. [NCT02492711](https://clinicaltrials.gov/ct2/show/NCT02492711)\n24. [NCT01554371](https://clinicaltrials.gov/ct2/show/NCT01554371)\n25. [NCT01427933](https://clinicaltrials.gov/ct2/show/NCT01427933)\n26. [NCT01596751](https://clinicaltrials.gov/ct2/show/NCT01596751)\n27. [NCT01156753](https://clinicaltrials.gov/ct2/show/NCT01156753)\n\nYou can click on the links to view detailed information about each study. Let me know if you'd like further details on any specific study.",
  "18": "The PMID of the article is **40320805**. Let me know if you'd like more details or assistance with anything else!",
  "19": "Here are the NCT IDs of completed interventional studies for Non-Hodgkin's Lymphoma involving Lenalidomide that started in August 2005 in the United States:\n\n1. NCT00179660\n2. NCT00238238\n3. NCT00294632\n4. NCT00413036\n5. NCT00695786\n6. NCT00737529\n7. NCT00765245\n8. NCT00783367\n9. NCT00784927\n10. NCT00864942\n11. NCT01035463\n12. NCT01060384\n13. NCT01075321\n14. NCT01076543\n15. NCT01088048\n16. NCT01145495\n17. NCT01197560\n18. NCT01254578\n19. NCT01316523\n20. NCT01429025\n21. NCT01476787\n22. NCT01755975\n23. NCT01919619\n24. NCT01938001\n25. NCT01995669\n26. NCT01996865\n27. NCT02561273\n28. NCT03019640\n29. NCT04578600\n\nLet me know if you'd like more details about any of these studies.",
  "20": "The unique PMID for the article titled “Complexity of neuro-oncological in-hospital consultations: a multicentre study” by Jauregui Larrañaga C, published in *Neurologia* in 2025, is **40306462**.",
  "21": "Here is a list of completed interventional studies for Type 2 Diabetes Mellitus that started in August 2007 in the United States, as found in ClinicalTrials.gov:\n\n1. **NCT02202876**  \n2. **NCT01517373**  \n3. **NCT00935220**  \n4. **NCT01654120**  \n5. **NCT01073020**  \n6. **NCT02197520**  \n7. **NCT01676220**  \n8. **NCT03653091**  \n9. **NCT04347291**  \n10. **NCT02432391**  \n\n... and many more.  \n\nIf you'd like details on any specific study, let me know the NCT ID, and I can provide more information.",
  "22": "In the OpenTargets database, the target **MTOR** is associated with the event **heart disease** in the following way:\n\n- **Biosamples**: The cardiovascular system (tissue ID: `UBERON_0004535`) is implicated.\n- **Effects**: No specific effects are documented for this event in the database.\n\nIf you'd like further details or additional analysis, let me know!",
  "23": "The following diseases are associated with the target **ADRB1 (Ensembl ID ENSG00000043591)** with a minimum relevance score of 0.5 according to OpenTargets:\n\n1. **Hypertension** (Score: 0.738)\n2. **Cardiovascular disease** (Score: 0.723)\n3. **Myocardial infarction** (Score: 0.621)\n4. **Open-angle glaucoma** (Score: 0.605)\n5. **Glaucoma** (Score: 0.605)\n6. **Heart failure** (Score: 0.605)\n7. **Angina pectoris** (Score: 0.604)\n8. **Ocular hypertension** (Score: 0.602)\n9. **Migraine disorder** (Score: 0.602)\n10. **Congestive heart failure** (Score: 0.597)\n11. **Asthma** (Score: 0.596)\n12. **Sudden cardiac arrest** (Score: 0.590)\n13. **Ventricular arrhythmia** (Score: 0.583)\n14. **Sepsis** (Score: 0.582)\n15. **Pain** (Score: 0.581)\n16. **Sinusitis** (Score: 0.581)\n17. **Hypotension** (Score: 0.577)\n18. **Stroke** (Score: 0.576)\n19. **High density lipoprotein cholesterol measurement** (Score: 0.573)\n20. **Septic shock** (Score: 0.566)\n21. **Systolic blood pressure** (Score: 0.561)\n22. **Triglyceride measurement** (Score: 0.560)\n23. **Atrial fibrillation** (Score: 0.560)\n24. **Allergic disease** (Score: 0.559)\n25. **Diastolic blood pressure** (Score: 0.552)\n\nLet me know if you'd like more details about any of these associations!",
  "24": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Type+2+Diabetes+Mellitus&query.intr=exenatide+AND+long+acting+release+exenatide&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2006-04-01%2CMAX%5D",
  "25": "The target **DPEP1 (ENSG00000015413)** is associated with the following diseases in OpenTargets, with a minimum relevance score of 0.5:\n\n1. **Infection** (Score: 0.579)\n2. **Urinary tract infection** (Score: 0.572)\n3. **Body height** (Score: 0.569)\n4. **Sepsis** (Score: 0.566)\n5. **Pneumonia** (Score: 0.565)\n6. **Diastolic blood pressure** (Score: 0.563)\n7. **Endocarditis** (Score: 0.559)\n8. **Cysteinylglycine measurement** (Score: 0.557)\n9. **Cys-gly, oxidized measurement** (Score: 0.553)\n10. **Cysteinylglycine disulfide measurement** (Score: 0.545)\n11. **Osteoarthritis** (Score: 0.522)\n\nLet me know if you'd like more details about any of these associations!",
  "26": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "27": "It appears that the article titled “Hepatology in the Digital Era: A Review of Telehealth Care for Liver Disease,” authored by Bloomberg L and published in *Current Gastroenterology Reports* in 2025, is not indexed in PubMed as of now. \n\nIf you have additional details or if the article might be published under a slightly different title or journal, I can refine the search further. Alternatively, you may want to check other databases or the journal's website directly. Let me know how you'd like to proceed!",
  "28": "The PMID of the article titled \"[Transition in gastroenterology and hepatology]\" by Siegmund B, published in 2025, is **40358755**.",
  "29": "The following diseases are associated with the target MTOR (Ensembl ID ENSG00000198793) in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome**  \n   - Score: 0.829  \n   - Disease ID: EFO_0009050\n\n2. **Isolated focal cortical dysplasia type II**  \n   - Score: 0.817  \n   - Disease ID: MONDO_0011818\n\n3. **Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes**  \n   - Score: 0.653  \n   - Disease ID: MONDO_0100283\n\n4. **Neurodegenerative disease**  \n   - Score: 0.560  \n   - Disease ID: EFO_0005772\n\n5. **Clear cell renal carcinoma**  \n   - Score: 0.544  \n   - Disease ID: EFO_0000349\n\n6. **CEBALID syndrome**  \n   - Score: 0.524  \n   - Disease ID: MONDO_0032908  \n\nLet me know if you'd like more details about any of these associations!",
  "30": "Here is a list of completed interventional studies for Myelodysplastic Syndromes involving Azacitidine that started in November 2003 in the United States, as found on ClinicalTrials.gov:\n\n1. **NCT00324220**  \n2. **NCT00352001**  \n3. **NCT00313586**  \n4. **NCT00326170**  \n5. **NCT00350818**  \n6. **NCT00351975**  \n7. **NCT00357708**  \n8. **NCT00382590**  \n9. **NCT00384956**  \n\nThese studies meet the criteria of being completed, involving Azacitidine, and starting in November 2003 in the United States. Let me know if you'd like more details about any of these studies.",
  "31": "The following diseases are associated with the target IL13 (Ensembl ID: ENSG00000169194) with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Atopic eczema** (Score: 0.699)\n2. **Asthma** (Score: 0.678)\n3. **Eczematoid dermatitis** (Score: 0.615)\n4. **Allergic rhinitis** (Score: 0.567)\n5. **Psoriasis** (Score: 0.549)",
  "32": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "33": "The target **ANGPT1** (Ensembl ID ENSG00000154188) is associated with the following diseases in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Open-angle glaucoma** (Score: 0.548)\n2. **Intraocular pressure measurement** (Score: 0.513)",
  "34": "The PMID for the article is **40445929**.",
  "35": "Here is a list of completed interventional studies for Migraine Disorders that started in July 2008 in the United States, as found in ClinicalTrials.gov:\n\n1. **NCT00714727**\n2. **NCT00810368**\n3. **NCT00843024**\n4. **NCT00868556**\n5. **NCT00892203**\n6. **NCT00893737**\n7. **NCT00915473**\n8. **NCT00920686**\n9. **NCT00989625**\n10. **NCT01004835**\n11. **NCT01016834**\n12. **NCT01016678**\n13. **NCT01016834**\n14. **NCT01071317**\n15. **NCT01086358**\n16. **NCT01090050**\n17. **NCT01114815**\n18. **NCT01118988**\n19. **NCT01138150**\n20. **NCT01182051**\n21. **NCT01197196**\n22. **NCT01211145**\n23. **NCT01211795**\n24. **NCT01216358**\n25. **NCT01225263**\n26. **NCT01248468**\n27. **NCT01257880**\n28. **NCT01265797**\n29. **NCT01267864**\n30. **NCT01287052**\n31. **NCT01291758**\n32. **NCT01294046**\n33. **NCT01300546**\n34. **NCT01314651**\n35. **NCT01329562**\n36. **NCT01332864**\n37. **NCT01391091**\n38. **NCT01393522**\n39. **NCT01445067**\n40. **NCT01450995**\n41. **NCT01462812**\n42. **NCT01462812**\n43. **NCT01431326**\n44. **NCT01430442**\n45. **NCT01445067**\n46. **NCT01450995**\n47. **NCT01462812**\n48. **NCT01431326**\n49. **NCT01430442**\n50. **NCT01445067**\n\nThis list includes the NCT IDs of the studies. If you'd like more details about any specific study, let me know!",
  "36": "The following interventional studies for Clostridium Infections or Diarrhea involving PAR-101/OPT-80 or Vancomycin started in October 2006 in the United States:\n\n1. **NCT00468728**  \n2. **NCT02692651**  \n\nYou can view the details of these studies on [ClinicalTrials.gov](https://clinicaltrials.gov/) by searching for their respective NCT IDs. Let me know if you'd like more information about any of them.",
  "37": "The following diseases are associated with the target GABRA2 (Ensembl ID ENSG00000151834) with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Alcohol dependence** - Score: 0.682\n2. **Epilepsy** - Score: 0.609\n3. **Major depressive disorder** - Score: 0.609\n4. **Insomnia** - Score: 0.605\n5. **Panic disorder** - Score: 0.603\n6. **Agitation** - Score: 0.603\n7. **Anxiety disorder** - Score: 0.602\n8. **Anxiety** - Score: 0.600\n9. **Migraine disorder** - Score: 0.595\n10. **Seizure** - Score: 0.589\n11. **Pain** - Score: 0.578\n12. **Depressive disorder** - Score: 0.566\n13. **Generalized anxiety disorder** - Score: 0.556\n14. **Postpartum depression** - Score: 0.555\n15. **Lennox-Gastaut syndrome** - Score: 0.553\n16. **Status epilepticus** - Score: 0.548\n17. **Developmental and epileptic encephalopathy** - Score: 0.536\n18. **Stiff-Person syndrome** - Score: 0.526\n\nLet me know if you'd like more details about any of these associations!",
  "38": "The unique PMID for the article is **40167622**.",
  "39": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Relapsing-Remitting+Multiple+Sclerosis&query.intr=BG00012&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2007-01-01%2CMAX%5D",
  "40": "For the target with Ensembl ID **ENSG00000196230** (approved symbol **TUBB**), the following tractability information is available where the value is **True**:\n\n1. **Small Molecule (SM) Modality**:\n   - Approved Drug\n   - Structure with Ligand\n   - High-Quality Ligand\n   - Druggable Family\n\n2. **Antibody (AB) Modality**:\n   - GO CC high conf\n\n3. **Proteolysis (PR) Modality**:\n   - UniProt Ubiquitination\n   - Database Ubiquitination\n   - Half-life Data\n   - Small Molecule Binder\n\n4. **Other Clinical (OC) Modality**:\n   - Approved Drug\n\nThis indicates that TUBB is tractable through multiple modalities, including small molecules, antibodies, and proteolysis, with several high-confidence features.",
  "41": "Here are the NCT IDs of completed interventional studies for Type 2 Diabetes Mellitus involving Exenatide Once Weekly conducted in the United States:\n\n1. NCT00803920  \n2. NCT01652729  \n3. NCT01104701  \n4. NCT00637273  \n5. NCT00806520  \n6. NCT02288273  \n7. NCT02917057  \n8. NCT00717457  \n9. NCT03970044  \n10. NCT02974244  \n11. NCT02981069  \n12. NCT00103935  \n13. NCT00308139  \n14. NCT00894322  \n15. NCT00753896  \n16. NCT02229396  \n17. NCT02251431  \n18. NCT01652716  \n19. NCT01885208  \n20. NCT02119819  \n21. NCT01554618  \n22. NCT02843399  \n23. NCT01144338  \n24. NCT01064687  \n25. NCT00641056  \n26. NCT00676338  \n27. NCT00877890  \n28. NCT02229383  \n\nLet me know if you'd like more details about any of these studies.",
  "42": "It seems the article titled \"[Practical guideline for short bowel syndrome]\" by Dabsch S, published in Zeitschrift fur Gastroenterologie in 2025, is not available in PubMed or may not be indexed yet. Would you like me to try a broader search or check another database?",
  "43": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "44": "The target **TYMS (ENSG00000176890)** is associated with the following diseases in OpenTargets, with a minimum relevance score of 0.5:\n\n1. **Dyskeratosis congenita, digenic** (Score: 0.662)\n2. **Breast cancer** (Score: 0.616)\n3. **Neoplasm** (Score: 0.613)\n4. **Dyskeratosis congenita** (Score: 0.598)\n5. **Non-small cell lung carcinoma** (Score: 0.594)\n6. **Breast carcinoma** (Score: 0.580)\n7. **Colonic neoplasm** (Score: 0.576)\n8. **Actinic keratosis** (Score: 0.571)\n9. **Colorectal neoplasm** (Score: 0.554)\n10. **Breast neoplasm** (Score: 0.553)\n11. **Mesothelioma** (Score: 0.547)\n12. **Stomach neoplasm** (Score: 0.528)\n13. **Gastric adenocarcinoma** (Score: 0.524)\n14. **Adenocarcinoma** (Score: 0.509)\n15. **Arabonate measurement** (Score: 0.501)\n\nLet me know if you'd like more details about any of these associations!",
  "45": "The tractability information for the target with Ensembl ID **ENSG00000163599** (approved symbol **CTLA4**) where the value is **True** includes the following modalities:\n\n1. **SM (Small Molecule)**:\n   - **Label**: Structure with Ligand\n   - **Value**: True\n\n2. **AB (Antibody)**:\n   - **Label**: Approved Drug\n   - **Value**: True\n   - **Label**: UniProt loc high conf\n   - **Value**: True\n   - **Label**: GO CC high conf\n   - **Value**: True\n   - **Label**: UniProt SigP or TMHMM\n   - **Value**: True\n\nThis indicates that CTLA4 is tractable for both small molecule and antibody modalities, with high confidence in its localization and functional annotations.",
  "46": "There are numerous completed interventional studies for chronic myelogenous leukemia (CML) that started in July 2007 in the United States. Here is a list of the NCT IDs for these studies:\n\n1. NCT02397720  \n2. NCT03045120  \n3. NCT01772420  \n4. NCT00469729  \n5. NCT03578367  \n6. NCT02129101  \n7. NCT01607892  \n8. NCT01053494  \n9. NCT00660920  \n10. NCT01629082  \n11. NCT03096782  \n12. NCT00513474  \n13. NCT05743465  \n14. NCT02556931  \n15. NCT01110473  \n16. NCT01529827  \n17. NCT00964873  \n18. NCT03860376  \n19. NCT00809276  \n20. NCT02530476  \n... (and many more)\n\nIf you'd like detailed information about any specific study, please let me know the NCT ID(s) you're interested in.",
  "47": "For the target with Ensembl ID **ENSG00000117601** (approved symbol **SERPINC1**), the following tractability information is available where the value is **True**:\n\n1. **Small Molecule (SM) Modality**:\n   - Structure with Ligand\n   - High-Quality Pocket\n   - Druggable Family\n\n2. **Antibody (AB) Modality**:\n   - GO CC high confidence\n   - UniProt location medium confidence\n   - UniProt SignalP or TMHMM\n\n3. **Proteolysis Targeting Chimera (PR) Modality**:\n   - Small Molecule Binder\n\n4. **Other Clinical (OC) Modality**:\n   - Approved Drug\n\nThis indicates that **SERPINC1** is tractable across multiple modalities, including small molecules, antibodies, and proteolysis targeting chimeras, with some evidence supporting its druggability.",
  "48": "The tractability information for the target with Ensembl ID **ENSG00000091879** (approved symbol **ANGPT2**) where the value is **True** includes the following modalities:\n\n1. **AB (Antibody)**:\n   - Approved Drug\n   - UniProt location high confidence\n   - GO Cellular Component high confidence\n   - UniProt Signal Peptide or TMHMM\n\n2. **OC (Other Clinical)**:\n   - Advanced Clinical\n\nThis indicates that ANGPT2 is tractable for antibody-based approaches and has advanced clinical relevance.",
  "49": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Heart+Failure%2C+Congestive+OR+Dilated+Cardiomyopathy&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2007-03-01%2CMAX%5D",
  "50": "The unique PMID for the article is **40405078**.",
  "51": "Here are the completed interventional studies for Multiple Sclerosis involving Fingolimod 1.25 mg as an intervention that started in May 2006 in the United States:\n\n1. **NCT00355134**  \n2. **NCT00340834**  \n3. **NCT03623243**  \n\nYou can find more details about these studies on [ClinicalTrials.gov](https://clinicaltrials.gov/) by searching for their respective NCT IDs.",
  "52": "The PMID of the article is **40306647**.",
  "53": "The following diseases are associated with the target DRD2 (Ensembl ID ENSG00000149295) with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Major depressive disorder** (Score: 0.731)\n2. **Schizophrenia** (Score: 0.705)\n3. **Bipolar disorder** (Score: 0.685)\n4. **Mental or behavioural disorder** (Score: 0.641)\n5. **Parkinson disease** (Score: 0.637)\n6. **Tourette syndrome** (Score: 0.629)\n7. **Autism** (Score: 0.616)\n8. **Psychosis** (Score: 0.615)\n9. **Schizoaffective disorder** (Score: 0.606)\n10. **Bipolar I disorder** (Score: 0.603)\n11. **Agitation** (Score: 0.600)\n12. **Aggressive behavior** (Score: 0.599)\n13. **Restless legs syndrome** (Score: 0.593)\n14. **Depressive disorder** (Score: 0.590)\n15. **Nausea and vomiting** (Score: 0.575)\n16. **Post operative nausea and vomiting** (Score: 0.569)\n17. **Type 2 diabetes mellitus** (Score: 0.547)\n18. **Gastrointestinal disease** (Score: 0.538)\n19. **Hypogonadism** (Score: 0.526)\n20. **Conduct disorder** (Score: 0.520)\n21. **Hyperprolactinemia** (Score: 0.516)\n22. **Infertility** (Score: 0.513)\n23. **Acromegaly** (Score: 0.504)\n\nLet me know if you'd like more details about any of these associations!",
  "54": "Yes, the tractability information for the target with Ensembl ID **ENSG00000185499** (approved symbol **MUC1**) indicates that it has multiple modalities with the value set to **True**. These include:\n\n1. **Small Molecule (SM)**:\n   - Structure with Ligand\n   - Med-Quality Pocket\n\n2. **Antibody (AB)**:\n   - Advanced Clinical\n   - UniProt loc high conf\n   - GO CC high conf\n   - UniProt loc med conf\n   - UniProt SigP or TMHMM\n   - Human Protein Atlas loc\n\n3. **Other Clinical (OC)**:\n   - Advanced Clinical\n\nThis suggests that MUC1 is tractable for various therapeutic approaches.",
  "55": "Here are the NCT IDs of completed interventional studies for Multiple Sclerosis involving Fingolimod that started in June 2006 or later in the United States:\n\n1. NCT01442194  \n2. NCT05141669  \n3. NCT01216072  \n4. NCT02021162  \n5. NCT04353492  \n6. NCT05528666  \n7. NCT01281657  \n8. NCT02776072  \n9. NCT03257358  \n10. NCT02141022  \n11. NCT00355134  \n12. NCT05684016  \n13. NCT01623596  \n14. NCT01285479  \n15. NCT03399981  \n16. NCT03623243  \n17. NCT03243721  \n18. NCT01201356  \n19. NCT01592097  \n20. NCT02225977  \n21. NCT02307877  \n22. NCT05060354  \n\nYou can look up these studies on [ClinicalTrials.gov](https://clinicaltrials.gov/) for more details. Let me know if you'd like further information about any of them!",
  "56": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Hepatitis+C&query.intr=Pegylated+Interferon+Alfa+2a&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2008-03-01%2CMAX%5D",
  "57": "The unique PubMed ID (PMID) for the article titled \"[Evolution of enterology as a science]\" by Sabelnikova EA, published in *Terapevticheskii arkhiv* in 2025, is **40237759**.",
  "58": "For the target **AKT1** (Ensembl ID: ENSG00000142208), the following tractability information is available where the value is **True**:\n\n### Small Molecule (SM) Modality:\n1. **Advanced Clinical**\n2. **Structure with Ligand**\n3. **High-Quality Ligand**\n4. **High-Quality Pocket**\n5. **Druggable Family**\n\n### Antibody (AB) Modality:\n1. **UniProt loc high conf**\n2. **GO CC high conf**\n\n### Proteolysis (PR) Modality:\n1. **Literature**\n2. **UniProt Ubiquitination**\n3. **Database Ubiquitination**\n4. **Half-life Data**\n5. **Small Molecule Binder**\n\nThese indicate that AKT1 is highly tractable across multiple modalities, particularly in small molecule and antibody-based approaches.",
  "59": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Melanoma&query.intr=ipilimumab&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2006-04-01%2CMAX%5D",
  "60": "For the target with Ensembl ID **ENSG00000151834** (approved symbol **GABRA2**), the following tractability information is available where the value is **True**:\n\n### Small Molecule (SM) Modality:\n1. **Approved Drug**: True  \n2. **High-Quality Ligand**: True  \n3. **Druggable Family**: True  \n\n### Antibody (AB) Modality:\n4. **GO CC high conf**: True  \n5. **UniProt loc med conf**: True  \n6. **UniProt SigP or TMHMM**: True  \n7. **Human Protein Atlas loc**: True  \n\n### Protein (PR) Modality:\n8. **Half-life Data**: True  \n9. **Small Molecule Binder**: True  \n\nThis indicates that GABRA2 is tractable across multiple modalities, including small molecules, antibodies, and protein-related approaches.",
  "61": "Here are the completed interventional studies for Multiple Sclerosis involving Laquinimod that started in November 2007 in the United States:\n\n1. **NCT01707992**  \n2. **NCT02284568**  \n3. **NCT00605215**  \n4. **NCT00509145**  \n\nYou can find more details about each study by visiting their respective pages on ClinicalTrials.gov. Let me know if you'd like further information about any of these studies!",
  "62": "For the target with Ensembl ID **ENSG00000176890** (approved symbol **TYMS**), the following tractability information is available where the value is **True**:\n\n### Small Molecule (SM) Modality:\n1. **Approved Drug**\n2. **Structure with Ligand**\n3. **High-Quality Ligand**\n4. **High-Quality Pocket**\n5. **Druggable Family**\n\n### Proteomics (PR) Modality:\n1. **UniProt Ubiquitination**\n2. **Database Ubiquitination**\n3. **Small Molecule Binder**\n\nThese indicate that TYMS is tractable for drug development, particularly through small molecule approaches, and has relevant proteomics data supporting its tractability.",
  "63": "The PMID of the article titled \"[Allergology: what's new in 2024],\" authored by Pérez-Codesido S and published in *Revue medicale suisse* in 2025, is **39812277**.",
  "64": "The unique PMID for the article titled \"The State of Immunology in Allergy and Immunology Fellowship,\" authored by Tran HN and published in *Immunology and Allergy Clinics of North America* in 2025, is **40287165**.",
  "65": "The article titled “Causal association between gut microbiota and endometrial cancer in European and East Asian populations: a two-sample Mendelian randomization study,” authored by Chen J and published in BMC Women's Health in 2025, does not appear to be indexed in PubMed yet. \n\nIf you have additional details or if the article is very recent, it might not yet be available in PubMed. You could try checking the journal's website or other databases for the PMID. Let me know if you'd like assistance with alternative search methods!",
  "66": "The article titled “Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics,” authored by Rosenbloom M and published in the Journal of Neurology in 2025, does not appear to be indexed in PubMed based on the provided details. \n\nIf you have additional information or if there might be an error in the title, author, journal, or publication year, please let me know, and I can refine the search.",
  "67": "The PMID of the article titled “Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing,” authored by Behel V and published in *NPJ Systems Biology and Applications* in 2025, is **40483308**.",
  "68": "For the target with Ensembl ID **ENSG00000188389** (approved symbol **PDCD1**), the following tractability information is available where the value is **True**:\n\n1. **Small Molecule (SM)**:\n   - Structure with Ligand\n   - High-Quality Ligand\n\n2. **Antibody (AB)**:\n   - Approved Drug\n   - UniProt loc high conf\n   - GO CC high conf\n   - UniProt SigP or TMHMM\n\n3. **Protein (PR)**:\n   - Literature\n   - UniProt Ubiquitination\n   - Small Molecule Binder\n\n4. **Other Clinical (OC)**:\n   - Advanced Clinical\n\nThis indicates that PDCD1 is tractable across multiple modalities, including small molecules, antibodies, and protein-based approaches, with evidence supporting its potential as a drug target.",
  "69": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Obesity+OR+Type+2+Diabetes&query.intr=VI-0521&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2007-11-01%2CMAX%5D",
  "70": "In the OpenTargets database, the target symbol **HRH1** is associated with the event **allergic responses of flare, flush, and wheal** in the following ways:\n\n### Biosamples:\n1. **Cardiovascular System** (UBERON_0004535)\n2. **Immune System** (UBERON_0002405)\n\n### Effects:\n- **Dosing**: General\n- **Direction**: Activation/Increase/Upregulation\n\nThis indicates that HRH1 plays a role in allergic responses, particularly in the cardiovascular and immune systems, with its activation or upregulation contributing to these reactions.",
  "71": "The unique PubMed ID (PMID) for the article titled \"Assessing the prevalence, quality and compliance of data-sharing statements in gastroenterology publications: a cross-sectional analysis,\" authored by Moore J and published in BMJ Open in 2025, is **40132820**.",
  "72": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "73": "The tractability information for the target **INSR** (Ensembl ID: ENSG00000171105) with a value of **True** includes the following modalities and labels:\n\n### Small Molecule (SM)\n- Advanced Clinical\n- Structure with Ligand\n- High-Quality Ligand\n- High-Quality Pocket\n- Druggable Family\n\n### Antibody (AB)\n- GO CC high conf\n- UniProt loc med conf\n- UniProt SigP or TMHMM\n- Human Protein Atlas loc\n\n### Proteolysis (PR)\n- Database Ubiquitination\n- Half-life Data\n- Small Molecule Binder\n\n### Other Clinical (OC)\n- Approved Drug\n\nThis indicates that INSR is highly tractable across multiple therapeutic modalities.",
  "74": "The target **HMGCR (ENSG00000113161)** is associated with the following diseases in OpenTargets, with a minimum relevance score of 0.5:\n\n1. **Coronary artery disease** (Score: 0.735)\n2. **Hypercholesterolemia** (Score: 0.713)\n3. **Familial hypercholesterolemia** (Score: 0.706)\n4. **Stroke** (Score: 0.689)\n5. **Cardiovascular disease** (Score: 0.668)\n6. **Type 2 diabetes mellitus** (Score: 0.662)\n7. **Hyperlipidemia** (Score: 0.635)\n8. **Low density lipoprotein cholesterol measurement** (Score: 0.618)\n9. **Myocardial infarction** (Score: 0.613)\n10. **Angina pectoris** (Score: 0.606)\n11. **Congestive heart failure** (Score: 0.602)\n12. **Abnormal circulating lipid concentration** (Score: 0.601)\n13. **Alzheimer disease** (Score: 0.587)\n14. **Atherosclerosis** (Score: 0.586)\n15. **Diabetes mellitus** (Score: 0.586)\n16. **Apolipoprotein B measurement** (Score: 0.584)\n17. **Total cholesterol measurement** (Score: 0.580)\n18. **Hypertension** (Score: 0.579)\n19. **Very low density lipoprotein cholesterol measurement** (Score: 0.577)\n20. **Neurodegenerative disease** (Score: 0.570)\n21. **Cholesteryl ester measurement** (Score: 0.568)\n22. **Lipid measurement** (Score: 0.566)\n23. **Phospholipids:total lipids ratio** (Score: 0.564)\n24. **Cholesterol:total lipids ratio** (Score: 0.564)\n25. **Multiple sclerosis** (Score: 0.563)\n\nThese associations highlight the role of HMGCR in lipid metabolism and cardiovascular diseases. Let me know if you'd like more details on any of these!",
  "75": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=malignant+melanoma&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2005-12-01%2CMAX%5D",
  "76": "The following diseases are associated with the target ENSG00000082175 (PGR) in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Endometriosis** (Score: 0.6567)\n2. **Uterine fibroid** (Score: 0.6512)\n3. **Acne** (Score: 0.5976)\n4. **Hemorrhage** (Score: 0.5757)\n5. **Menorrhagia** (Score: 0.5600)\n6. **Premature birth** (Score: 0.5522)\n7. **Anorexia** (Score: 0.5454)\n8. **Amenorrhea** (Score: 0.5382)\n9. **Leiomyoma** (Score: 0.5296)\n10. **Cachexia** (Score: 0.5259)\n11. **Neoplasm** (Score: 0.5247)\n12. **Cushing syndrome** (Score: 0.5110)\n13. **Inborn error of immunity** (Score: 0.5040)",
  "77": "The tractability information for the target with Ensembl ID **ENSG00000134853** (approved symbol **PDGFRA**) where the value is **True** includes the following modalities:\n\n### Small Molecule (SM)\n- **Approved Drug**: True\n- **Structure with Ligand**: True\n- **High-Quality Ligand**: True\n- **Druggable Family**: True\n\n### Antibody (AB)\n- **Approved Drug**: True\n- **UniProt loc high conf**: True\n- **GO CC high conf**: True\n- **UniProt SigP or TMHMM**: True\n\n### Proteolysis (PR)\n- **UniProt Ubiquitination**: True\n- **Database Ubiquitination**: True\n- **Half-life Data**: True\n- **Small Molecule Binder**: True\n\n### Other (OC)\n- **Approved Drug**: True\n\nThis indicates that PDGFRA is highly tractable across multiple therapeutic modalities. Let me know if you'd like further details!",
  "78": "The target **NR3C1** (Ensembl ID: ENSG00000113580) is associated with the following diseases, each with a relevance score of at least 0.5 in OpenTargets:\n\n1. **Glucocorticoid resistance** - Score: 0.7915\n2. **Chronic obstructive pulmonary disease** - Score: 0.7046\n3. **Multiple sclerosis** - Score: 0.6841\n4. **Frozen shoulder** - Score: 0.6436\n5. **Rheumatoid arthritis** - Score: 0.6318\n6. **Ulcerative colitis** - Score: 0.6183\n7. **Autoimmune thrombocytopenic purpura** - Score: 0.6175\n8. **Infection** - Score: 0.6143\n9. **Sarcoidosis** - Score: 0.6122\n10. **Nephrotic syndrome** - Score: 0.6104\n11. **Crohn's disease** - Score: 0.6096\n12. **Asthma** - Score: 0.6093\n13. **Cancer** - Score: 0.6087\n14. **Lymphoma** - Score: 0.6085\n15. **Osteoarthritis** - Score: 0.6083\n16. **Atopic eczema** - Score: 0.6075\n17. **Leukemia** - Score: 0.6072\n18. **Inflammation** - Score: 0.6070\n19. **Allergic rhinitis** - Score: 0.6070\n20. **Psoriasis** - Score: 0.6061\n21. **Pneumonia** - Score: 0.6049\n22. **Skin disease** - Score: 0.6042\n23. **Juvenile idiopathic arthritis** - Score: 0.6037\n24. **Seasonal allergic rhinitis** - Score: 0.6012\n25. **Psoriasis vulgaris** - Score: 0.6004\n\nLet me know if you'd like more details about any of these associations!",
  "79": "The following diseases are associated with the target RAF1 (Ensembl ID ENSG00000132155) with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Noonan syndrome** - Score: 0.874\n2. **Noonan syndrome with multiple lentigines** - Score: 0.806\n3. **Dilated cardiomyopathy** - Score: 0.753\n4. **Rasopathy** - Score: 0.675\n5. **Cancer** - Score: 0.632\n6. **Hypertrophic cardiomyopathy** - Score: 0.569\n7. **Costello syndrome** - Score: 0.561\n8. **Renal cell carcinoma** - Score: 0.528\n9. **Abnormality of the cardiovascular system** - Score: 0.528\n10. **Neoplasm** - Score: 0.522\n11. **Noonan syndrome and Noonan-related syndrome** - Score: 0.515\n12. **Hepatocellular carcinoma** - Score: 0.509\n\nLet me know if you'd like more details about any of these associations!",
  "80": "The PMID of the article titled “Mapping training programs for endoscopy nurses in gastroenterology: a scoping review,” authored by Parrella A and published in the European Journal of Gastroenterology & Hepatology in 2025, is **40207485**.",
  "81": "The unique PMID for the article titled “A decade of whole-exome sequencing in Brazilian Neurology: from past insights to future perspectives,” authored by Quaio CRDC, is **40360003**.",
  "82": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Multiple+Myeloma&query.intr=bortezomib&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2004-12-01%2CMAX%5D",
  "83": "The PMID of the article is **40499918**. Let me know if you'd like more details or assistance with anything else!",
  "84": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=Breast+Cancer&query.locn=%22United+States%22&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2007-01-01%2CMAX%5D",
  "85": "In the OpenTargets database, the following information is available about the event \"increased cardiac output\" for the target symbol **GABRA5**:\n\n### Biosamples:\n1. **Central Nervous System** (Tissue ID: UBERON_0001017)\n2. **Cardiovascular** (Tissue ID: UBERON_0004535)\n\n### Effects:\n- **Dosing**: Acute\n- **Direction**: Activation/Increase/Upregulation\n\nThis indicates that the event is associated with acute dosing and involves an increase or upregulation in cardiac output, observed in both the central nervous system and cardiovascular tissues.",
  "86": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "87": "[ERROR] 400 Client Error: Bad Request for url: https://clinicaltrials.gov/api/v2/studies?pageSize=100&countTotal=false&markupFormat=markdown&query.cond=metastatic+colorectal+cancer&query.intr=panitumumab+AND+FOLFIRI&filter.overallStatus=ACTIVE&filter.advanced=AREA%5BStartDate%5DRANGE%5B2006-06-01%2CMAX%5D",
  "88": "[ERROR] 'NoneType' object is not subscriptable",
  "89": "For the target with Ensembl ID **ENSG00000149295** (approved symbol **DRD2**), the following tractability information is available where the value is **True**:\n\n1. **Small Molecule (SM) Modality**:\n   - Approved Drug\n   - Structure with Ligand\n   - High-Quality Ligand\n   - Druggable Family\n\n2. **Antibody (AB) Modality**:\n   - UniProt loc high conf\n   - GO CC high conf\n   - UniProt SigP or TMHMM\n\n3. **Proteolysis Targeting (PR) Modality**:\n   - Small Molecule Binder\n\n4. **Other Clinical (OC) Modality**:\n   - Approved Drug\n\nThis indicates that DRD2 is highly tractable across multiple modalities, particularly in small molecule and antibody-based approaches.",
  "90": "For the target with Ensembl ID **ENSG00000169083** (approved symbol **AR**), the following tractability information is available where the value is **True**:\n\n### Small Molecule (SM) Modality:\n1. **Approved Drug**\n2. **Structure with Ligand**\n3. **High-Quality Ligand**\n4. **High-Quality Pocket**\n5. **Druggable Family**\n\n### Antibody (AB) Modality:\n1. **GO CC high conf**\n\n### Proteolysis (PR) Modality:\n1. **Advanced Clinical**\n2. **Literature**\n3. **UniProt Ubiquitination**\n4. **Database Ubiquitination**\n5. **Small Molecule Binder**\n\nThis indicates that the target is highly tractable across multiple modalities, including small molecules, antibodies, and proteolysis-based approaches.",
  "91": "The following diseases are associated with the target **SSTR5 (ENSG00000162009)** with a minimum relevance score of 0.5 according to OpenTargets:\n\n1. **IGF-1 measurement** (Score: 0.648)  \n2. **Acromegaly** (Score: 0.607)  \n3. **Neoplasm** (Score: 0.582)  \n4. **Neuroendocrine neoplasm** (Score: 0.549)  \n5. **Carcinoid tumor** (Score: 0.525)",
  "92": "It seems there are no PubMed entries matching the 2025 PLoS Medicine article titled “The cardiology community begins to embrace obesity as an important target for cardiovascular health” authored by Sattar N. This could be because the article is not yet published or indexed in PubMed. Would you like me to check for similar articles or try a broader search?",
  "93": "The unique PMID for the article is **40483151**.",
  "94": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "95": "The completed interventional study for Beta-Thalassemia using LentiGlobin BB305 Drug Product that started in June 2017 in the United States is registered with the NCT ID: [NCT03207009](https://clinicaltrials.gov/ct2/show/NCT03207009). You can click the link for more details about the study.",
  "96": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "97": "The PMID of the article is **40262814**.",
  "98": "The PMID of the article titled “A rare case of rectal malignant melanoma with long-term survival: case report and literature review,” authored by Huang H and published in the *World Journal of Surgical Oncology* in 2025, is **40483466**.",
  "99": "The PMID of the article titled “Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study” is **40482190**."
}